Companies Iovance Biotherapeutics
Iovance Biotherapeutics (IOVA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Iovance Biotherapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers1st pct.Of 12 peer CEOs
CEO pay, last three years
- $4,794,680FY2023
- $10,953,193FY2024
- $1,888,175FY2025
CEO total pay was $1,888,175 in fiscal 2025, down from $10,953,193 in fiscal 2024.
FY2025: salary $800,000 · bonus $0 · stock awards $759,375 · option awards $0
Executives and directors
Daniel Kirby · CCOFrederick Vogt · CEOIgor Bilinsky · COORaj Puri · Chief Regulatory OfficerJean-Marc Bellemin · CFOCorleen Roche · CFOMatthew Rosinack · ExecutiveAthena Countouriotis · Independent DirectorIain Dukes · Chair of the BoardMichael Weiser · Independent DirectorRyan Maynard · Independent DirectorWayne P. Rothbaum · Independent DirectorWendy Yarno · Independent Director
Frequently asked questions
Who was the highest-paid executive at Iovance Biotherapeutics in fiscal 2025?
As disclosed, Daniel Kirby (Chief Commercial Officer) was the highest-paid executive at Iovance Biotherapeutics in fiscal 2025, with total compensation of $2,160,595.
How does Iovance Biotherapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Frederick Vogt's total compensation ranked at the 1st percentile of Iovance Biotherapeutics's disclosed peer group.
What is Iovance Biotherapeutics's CEO-to-median employee pay ratio?
As disclosed, Iovance Biotherapeutics's CEO-to-median employee pay ratio was 12.31:1.
How did shareholders vote on Iovance Biotherapeutics's executive compensation?
As disclosed, 81.63% of shareholders supported Iovance Biotherapeutics's executive compensation in the latest say-on-pay vote.
How much does Iovance Biotherapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Iovance Biotherapeutics reported total board compensation of $1,745,318 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel Kirby | $507,534 | $100,000 | $1,222,800 | $133,763 | $184,680 | $0 | $11,817 | $2,160,595 |
| Chief Commercial Officer | ||||||||
| Frederick Vogt | 800,000 | 0 | 759,375 | 0 | 312,000 | 0 | 16,800 | 1,888,175 |
| Interim Chief Executive Officer and President, General Counsel | ||||||||
| Corleen Roche | 243,288 | 50,000 | 387,000 | 574,830 | 194,400 | 0 | 6,462 | 1,455,979 |
| Chief Financial Officer | ||||||||
| Raj Puri | 671,935 | 0 | 474,620 | 0 | 181,423 | 0 | 13,800 | 1,341,778 |
| Chief Regulatory Officer | ||||||||
| Igor Bilinsky | 570,531 | 0 | 379,688 | 0 | 154,043 | 0 | 13,800 | 1,118,062 |
| Chief Operating Officer | ||||||||
| Matthew Rosinack | 433,511 | 18,750 | 239,193 | 0 | 91,037 | 0 | 0 | 782,491 |
| Interim Principal Financial Officer and Principal Accounting Officer | ||||||||
| Jean-Marc Bellemin | 277,454 | 0 | 379,688 | 0 | 0 | 0 | 5,962 | 663,104 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Daniel Kirby | $2,160,595 | — | — | — |
| Frederick Vogt | 1,888,175 | 10,953,193 | 4,794,680 | ↓ −9,065,018 |
| Corleen Roche | 1,455,979 | — | — | — |
| Raj Puri | 1,341,778 | 3,216,149 | — | ↓ −1,874,371 |
| Igor Bilinsky | 1,118,062 | 3,247,940 | 1,591,571 | ↓ −2,129,878 |
| Matthew Rosinack | 782,491 | — | — | — |
| Jean-Marc Bellemin | 663,104 | 3,247,940 | 1,709,283 | ↓ −2,584,836 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Iovance's compensation philosophy focuses on attracting, motivating, and retaining talented executive officers by offering competitive compensation with both annual and significant long-term components. The program emphasizes pay-for-performance, tying a significant percentage of compensation to the achievement of corporate and individual performance goals and long-term stockholder value.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Haigh & Company |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jean-Marc Bellemin | RSU | 2025-03-05 | — | — | 93,750 | — | $379,688 |
| Igor Bilinsky | RSU | 2025-03-05 | — | — | 93,750 | — | 379,688 |
| Matthew Rosinack | RSU | 2025-03-05 | — | — | 59,060 | — | 239,193 |
| Raj Puri | RSU | 2025-03-05 | — | — | 117,190 | — | 474,620 |
| Corleen Roche | RSU | 2025-08-06 | — | — | 150,000 | — | 387,000 |
| Frederick Vogt | RSU | 2025-03-05 | — | — | 187,500 | — | 759,375 |
| Corleen Roche | OPTION | 2025-08-06 | — | — | 300,000 | — | 574,830 |
| Daniel Kirby | PSU | 2025-12-03 | 60,000 | 120,000 | — | 150,000 | 265,200 |
| Daniel Kirby | OPTION | 2025-02-10 | — | — | 35,000 | — | 133,763 |
| Daniel Kirby | RSU | 2025-02-10 | — | — | 120,000 | — | 638,400 |
| Daniel Kirby | PSU | 2025-02-10 | 60,000 | 120,000 | — | 150,000 | 319,200 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jean-Marc Bellemin | $379,688 | $0 | $0 | 0.0% |
| Igor Bilinsky | 379,688 | 0 | 0 | 0.0% |
| Matthew Rosinack | 239,193 | 0 | 0 | 0.0% |
| Raj Puri | 474,620 | 0 | 0 | 0.0% |
| Corleen Roche | 387,000 | 0 | 574,830 | 0.0% |
| Frederick Vogt | 759,375 | 0 | 0 | 0.0% |
| Daniel Kirby | 638,400 | 584,400 | 133,763 | 43.1% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Igor Bilinsky | RSU | 3,517 | — | $9,601 |
| Matthew Rosinack | RSU | 3,907 | — | 10,666 |
| Igor Bilinsky | Option | 7,033 | 7.12 | — |
| Raj Puri | Option | 7,814 | 7.12 | — |
| Frederick Vogt | RSU | 10,418 | — | 28,441 |
| Raj Puri | RSU | 27,348 | — | 74,660 |
| Matthew Rosinack | RSU | 27,348 | — | 74,660 |
| Daniel Kirby | Option | 35,000 | 5.32 | — |
| Frederick Vogt | Option | 41,669 | 7.12 | — |
| Igor Bilinsky | RSU | 43,949 | — | 119,981 |
| Matthew Rosinack | RSU | 59,060 | — | 161,234 |
| Igor Bilinsky | RSU | 93,750 | — | 255,938 |
| Raj Puri | RSU | 117,190 | — | 319,929 |
| Daniel Kirby | RSU | 120,000 | — | 327,600 |
| Corleen Roche | RSU | 150,000 | — | 409,500 |
| Daniel Kirby | RSU | 150,000 | — | 409,500 |
| Frederick Vogt | RSU | 187,500 | — | 511,875 |
| Frederick Vogt | RSU | 208,344 | — | 568,779 |
| Corleen Roche | Option | 300,000 | 2.58 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael WeiserIndependent · Audit | $320,000 | $151,303 | $0 | $0 | $0 | $471,303 |
| Iain DukesIndependent · Board Chair · Nominating and Corporate Governance (Chair) | 90,000 | 302,606 | 0 | 0 | 0 | 392,606 |
| Wayne P. RothbaumIndependent · Scientific | 240,000 | 0 | 0 | 0 | 0 | 240,000 |
| Athena CountouriotisIndependent · Compensation · Nominating and Corporate Governance | 65,000 | 151,303 | 0 | 0 | 0 | 216,303 |
| Ryan MaynardIndependent · Audit | 65,000 | 151,303 | 0 | 0 | 0 | 216,303 |
| Wendy YarnoIndependent · Audit · Not standing for re-election | 57,500 | 151,303 | 0 | 0 | 0 | 208,803 |
| Frederick G. VogtEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $151,303 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $837,500 |
| Equity awards (grant-date value) | $907,818 |
| All other compensation | $0 |
| Total cost of the board | $1,745,318 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Iovance Biotherapeutics as a peer
Companies that benchmark against IOVA
20 companies name IOVA as a compensation peer
The list of companies that name IOVA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
RCUS Arcus Biosciences, Inc.BEAM Beam Therapeutics Inc.CRNX Crinetics Pharmaceuticals, Inc.DNLI Denali Therapeutics Inc.REPL Replimune Group, Inc.APLS Apellis Pharmaceuticals, Inc. Immunity Bio, Inc.XNCR Xencor, Inc.RARE Ultragenyx Pharmaceutical Inc.AGIO Agios Pharmaceuticals, Inc.CRSP Crispr Therapeutics AGCYTK Cytokinetics, Inc.
Peer reciprocity
The companies Iovance Biotherapeutics names as compensation peers that name it back in their own disclosed peer groups.
Beam Therapeutics Inc. (BEAM)103Crinetics Pharmaceuticals, Inc. (CRNX)104Denali Therapeutics Inc. (DNLI)105Xencor, Inc. (XNCR)106
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cytokinetics, Inc. | 2025 | Robert Blum | $853,069 | $5,150,019 | $5,095,918 | $772,715 | $11,881,456 |
| 2 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 3 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 4 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 5 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 6 | Crispr Therapeutics AG | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 7 | Replimune Group, Inc. | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 8 | Beam Therapeutics Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 9 | Xencor, Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 10 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 11 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 12 | Iovance Biotherapeutics | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Iovance Biotherapeutics | 60% | not disclosed | No | Haigh & Company |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Beam Therapeutics Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Crispr Therapeutics AG | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Cytokinetics, Inc. | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Replimune Group, Inc. | not disclosed | not disclosed | No | Pearl Meyer |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Xencor, Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 160,497,888 | 36,117,764 | 2,697,741 | 81.63% | Passed |
| 2025 | 2025-06-10 | 158,778,895 | 14,490,865 | 848,919 | 91.64% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 81.63%a |
| 2025 | 2025-06-10 | 91.64%b |
a. Approved under the standard stated in the filing — “Abstentions and broker "non-votes" will have no effect on this Proposal.”.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 12.31 : 1 |
|---|---|
| CEO total compensation | $1,888,175 |
| Median employee compensation | $153,409 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Daniel Kirby | Chief Commercial Officer | 2026-05-11 | D | 2,435 | $4 | $9,010 | Common | Form 4 ↗ |
| Daniel Kirby | Chief Commercial Officer | 2026-05-11 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Kirby | Chief Commercial Officer | 2026-05-11 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-06-01 | D | 8,790 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-06-01 | D | 4,473 | 4 | 17,713 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-06-01 | A | 8,790 | 0 | 0 | Common | Form 4 ↗ |
| Finckenstein Friedrich Graf | Chief Medical Officer | 2026-06-01 | A | 8,790 | 0 | 0 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-06-01 | D | 5,469 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-06-01 | D | 2,508 | 4 | 9,932 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-06-01 | A | 5,469 | 0 | 0 | Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-06-01 | D | 41,668 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Finckenstein Friedrich Graf | Chief Medical Officer | 2026-06-01 | D | 8,790 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-06-01 | A | 41,668 | 0 | 0 | Common | Form 4 ↗ |
| Finckenstein Friedrich Graf | Chief Medical Officer | 2026-06-01 | D | 4,473 | 4 | 17,713 | Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-06-01 | D | 17,701 | 4 | 70,096 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-06-05 | D | 7,813 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-06-05 | A | 7,813 | 0 | 0 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-06-05 | D | 9,766 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-06-05 | D | 3,843 | 4 | 16,256 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-06-05 | A | 9,766 | 0 | 0 | Common | Form 4 ↗ |
| Finckenstein Friedrich Graf | Chief Medical Officer | 2026-06-05 | D | 7,813 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Finckenstein Friedrich Graf | Chief Medical Officer | 2026-06-05 | A | 7,813 | 0 | 0 | Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-06-05 | D | 15,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-06-05 | D | 6,638 | 4 | 28,079 | Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-06-05 | A | 15,625 | 0 | 0 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-06-05 | D | 3,976 | 4 | 16,818 | Common | Form 4 ↗ |
| Finckenstein Friedrich Graf | Chief Medical Officer | 2026-06-05 | D | 3,976 | 4 | 16,818 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-06-16 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Weiser | Director | 2026-06-16 | A | 90,316 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Maynard | Director | 2026-06-16 | A | 90,316 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Iain Dukes | Director | 2026-06-16 | A | 180,632 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Athena Countouriotis | Director | 2026-06-16 | A | 90,316 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Corleen Roche | Chief Financial Officer | 2026-08-06 | D | 49,995 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Corleen Roche | Chief Financial Officer | 2026-08-06 | D | 21,238 | 6 | 131,888 | Common | Form 4 ↗ |
| Corleen Roche | Chief Financial Officer | 2026-08-06 | A | 49,995 | 0 | 0 | Common | Form 4 ↗ |
| Daniel Kirby | Chief Commercial Officer | 2026-08-10 | D | 10,001 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Kirby | Chief Commercial Officer | 2026-08-10 | D | 2,436 | 6 | 15,590 | Common | Form 4 ↗ |
| Daniel Kirby | Chief Commercial Officer | 2026-08-10 | A | 10,001 | 0 | 0 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-09-01 | D | 8,789 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-09-01 | D | 2,508 | 8 | 20,766 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-09-01 | A | 5,470 | 0 | 0 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-09-01 | A | 8,789 | 0 | 0 | Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-09-01 | A | 41,669 | 0 | 0 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-09-01 | D | 4,472 | 8 | 37,028 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-09-01 | D | 5,470 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-09-01 | D | 41,669 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-09-01 | D | 17,702 | 8 | 146,573 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-09-08 | A | 9,766 | 0 | 0 | Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-09-08 | D | 15,626 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-09-08 | D | 6,638 | 9 | 57,751 | Common | Form 4 ↗ |
| Frederick G. Vogt | Director | 2026-09-08 | A | 15,626 | 0 | 0 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-09-08 | A | 7,813 | 0 | 0 | Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-09-08 | D | 9,766 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raj Puri | Chief Regulatory Officer | 2026-09-08 | D | 4,478 | 9 | 38,959 | Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-09-08 | D | 7,813 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Igor Bilinsky | Chief Operating Officer | 2026-09-08 | D | 3,976 | 9 | 34,591 | Common | Form 4 ↗ |
| Noah Berkowitz | Chief Medical Officer | 2026-09-30 | A | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noah Berkowitz | Chief Medical Officer | 2026-09-30 | A | 180,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Noah Berkowitz | Chief Medical Officer | 2026-09-30 | A | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (106 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Daniel Kirby. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 2,160,595. View filing ↗
- Section 01, Frederick Vogt. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,888,175. View filing ↗
- Section 01, Corleen Roche. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,455,979. View filing ↗
- Section 01, Raj Puri. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,341,778. View filing ↗
- Section 01, Igor Bilinsky. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,118,062. View filing ↗
- Section 01, Matthew Rosinack. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 782,491. View filing ↗
- Section 01, Jean-Marc Bellemin. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 663,104. View filing ↗
- Section 03, Jean-Marc Bellemin RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Igor Bilinsky RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Rosinack RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Raj Puri RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Corleen Roche RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Frederick Vogt RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Corleen Roche OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Kirby PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Kirby OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Kirby RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Kirby PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 12.31 : 1. View filing ↗
- Section 08, Michael Weiser. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 471,303. View filing ↗
- Section 08, Iain Dukes. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 392,606. View filing ↗
- Section 08, Wayne P. Rothbaum. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 240,000. View filing ↗
- Section 08, Athena Countouriotis. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 216,303. View filing ↗
- Section 08, Ryan Maynard. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 216,303. View filing ↗
- Section 08, Wendy Yarno. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 208,803. View filing ↗
- Section 08, Frederick G. Vogt. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Daniel Kirby 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Kirby 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Kirby 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Finckenstein Friedrich Graf 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Finckenstein Friedrich Graf 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Finckenstein Friedrich Graf 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Finckenstein Friedrich Graf 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Finckenstein Friedrich Graf 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Finckenstein Friedrich Graf 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Weiser 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Maynard 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Iain Dukes 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Athena Countouriotis 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corleen Roche 2026-08-06. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corleen Roche 2026-08-06. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corleen Roche 2026-08-06. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Kirby 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Kirby 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Kirby 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frederick G. Vogt 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raj Puri 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Igor Bilinsky 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Berkowitz 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Berkowitz 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Noah Berkowitz 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 81.63% (votes for as printed: 160,497,888). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-10. Item 5.07 · say-on-pay result. As reported: 91.64% (votes for as printed: 158,778,895). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 837,500 + equity 907,818 + all other 0 = 1,745,318, summed across the director compensation table rows.
- Cytokinetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics, Inc.'s own proxy. As printed: 11,881,456. View filing ↗
- Crinetics Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. View filing ↗
- Ultragenyx Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- Crispr Therapeutics AG, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics AG's own proxy. As printed: 7,678,477. View filing ↗
- Replimune Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. View filing ↗
- Beam Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. View filing ↗
- Xencor, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Iovance Biotherapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Iovance Biotherapeutics's own proxy. As printed: 1,888,175. View filing ↗
- Section 10a, Beam Therapeutics Inc. reciprocity. DEF 14A. Beam Therapeutics Inc. names Iovance Biotherapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Crinetics Pharmaceuticals, Inc. reciprocity. DEF 14A. Crinetics Pharmaceuticals, Inc. names Iovance Biotherapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Denali Therapeutics Inc. reciprocity. DEF 14A. Denali Therapeutics Inc. names Iovance Biotherapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Xencor, Inc. reciprocity. DEF 14A. Xencor, Inc. names Iovance Biotherapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗